The present study aimed to compare the cardiovascular outcomes of two prominent classes of antidiabetic medications-SGLT2 inhibitorsand GLP-1 receptor agonists-in patients with type 2 diabetes mellitus (T2DM). This evidence concerns the gene SLC5A2 and diabetes mellitus.